Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2460-2026

directCHECK ACT-LR whole blood quality control, level 2 Recall

directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2

FDA recall Class II

Ongoing

FDA lists this Class II recall for directCHECK ACT-LR whole blood quality control, level 2. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2460-2026
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Apr 30, 2026
FDA report date
Jun 24, 2026
Quantity in commerce
6060
Distribution
See key details
FDA cause
Process control

What is being recalled?

directCHECK ACT-LR whole blood quality control, level 2 Model/Catalog Number: DCGLR-2

Affected model & UDI checker

Search the exact identifiers published for Z-2460-2026.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
DCGLR-2directCHECK ACT-LR whole blood quality control, level 2Check source noticeNot specified
FDA code information

Lot #: A6DLA001 Unique Device Identifier: 10711234170373

View the original FDA recall notice

Why was this product recalled?

Assayed Whole blood control contains labeling with incorrect performance range.

What actions did Accriva Diagnostics, Inc. take?

On May 8, 2026 Accriva Diagnostics, issued a Urgent Medical Device Recall Notification to affected consignees via E-Mail.. Accriva asked consignees to take the following actions: 1. Please forward this communication to those within your organization who need to become aware 2. Forward the enclosed customer notification to all other organizations where affected devices may have been transferred to. 3. Forward the enclosed customer notification to those in your organization that are responsible for performing quality control testing and/or supervise testing. 4. Please check your inventory to determine if you have any boxes of directCHECK Whole BloodControls. If you have this product in stock, do NOT use. 5. Please destroy all impacted boxes and document on the enclosed form. 6. Please read the instructions on the Tracking Form and complete and return the form to Accriva Diagnostics, Inc. 7. If you have any technical questions, please contact Technical Services at 1-800-678-0710 Option 3 or e-mail [email protected].

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology